MX2022005494A - Sistemas de residencia gastrica para la administracion de agentes activos. - Google Patents

Sistemas de residencia gastrica para la administracion de agentes activos.

Info

Publication number
MX2022005494A
MX2022005494A MX2022005494A MX2022005494A MX2022005494A MX 2022005494 A MX2022005494 A MX 2022005494A MX 2022005494 A MX2022005494 A MX 2022005494A MX 2022005494 A MX2022005494 A MX 2022005494A MX 2022005494 A MX2022005494 A MX 2022005494A
Authority
MX
Mexico
Prior art keywords
gastric residence
disclosed
administration
gastric
active agents
Prior art date
Application number
MX2022005494A
Other languages
English (en)
Spanish (es)
Inventor
Tyler Grant
Rosemary Kanasty
Jeanne Tran
Erick Peeke
David Altreuter
Marlene Schwarz
Sonia Holar
Alisha Weight
Saumya Moorthy
Tammy Tai
Juan Jaramillo Montezco
Jung Hoon Yang
Michelle Duan
Jie Jing
David C Dufour
Erik Robert Waldemar Ryde
Nupura Bhise
La Torre Nicholas De
Estelle Beguin
Craig Simses
Erica Lai
Original Assignee
Lyndra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyndra Therapeutics Inc filed Critical Lyndra Therapeutics Inc
Publication of MX2022005494A publication Critical patent/MX2022005494A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022005494A 2019-11-08 2020-11-06 Sistemas de residencia gastrica para la administracion de agentes activos. MX2022005494A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962933348P 2019-11-08 2019-11-08
US201962933210P 2019-11-08 2019-11-08
US201962933313P 2019-11-08 2019-11-08
US201962933211P 2019-11-08 2019-11-08
US201962933226P 2019-11-08 2019-11-08
US202062992075P 2020-03-19 2020-03-19
US202063052905P 2020-07-16 2020-07-16
PCT/US2020/059541 WO2021092491A1 (en) 2019-11-08 2020-11-06 Gastric residence systems for administration of active agents

Publications (1)

Publication Number Publication Date
MX2022005494A true MX2022005494A (es) 2022-08-11

Family

ID=75849597

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005494A MX2022005494A (es) 2019-11-08 2020-11-06 Sistemas de residencia gastrica para la administracion de agentes activos.

Country Status (10)

Country Link
US (1) US20220387311A1 (enExample)
EP (1) EP4054545A4 (enExample)
JP (1) JP2022553862A (enExample)
CN (1) CN115003335A (enExample)
AU (1) AU2020378438A1 (enExample)
BR (1) BR112022008908A2 (enExample)
CA (1) CA3160665A1 (enExample)
IL (1) IL292849A (enExample)
MX (1) MX2022005494A (enExample)
WO (1) WO2021092491A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
AU2020242062B2 (en) 2019-03-20 2025-12-11 Nortiva Bio, Inc. Coatings for gastric residence dosage forms
BR112021018496A2 (pt) 2019-03-20 2021-11-30 Lyndra Therapeutics Inc Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica
JP7847119B2 (ja) 2020-07-29 2026-04-16 ザ・セカント・グループ・エルエルシー 架橋ポリ(セバシン酸グリセロール)を含む構造を含む形状誘導型制御放出および保持
US20240390270A1 (en) * 2021-01-19 2024-11-28 Lyndra Therapeutics, Inc. Gastric residence systems for administration of risperidone
AU2023209872A1 (en) * 2022-01-19 2024-08-01 Nortiva Bio, Inc. Dosage forms for gastric retention
CN115227879B (zh) * 2022-09-15 2023-01-06 北京天星博迈迪医疗器械有限公司 一种用于可降解关节球囊的组合物及其应用、一种可降解关节球囊及其制备方法
US20240398701A1 (en) * 2023-06-02 2024-12-05 Lyndra Therapeutics, Inc. Manufacturing methods for gastric residence systems
WO2025042349A1 (en) * 2023-08-24 2025-02-27 Junion Therapeutics (Xiamen) Co., Ltd. A gastric residence article for oral administration
CN121752250A (zh) * 2023-08-24 2026-03-27 厦门君德医药科技有限公司 一种口服胃滞留物
WO2025148850A1 (zh) * 2024-01-09 2025-07-17 厦门君德医药科技有限公司 一种胃滞留装置
WO2025153071A1 (en) * 2024-01-18 2025-07-24 Junion Therapeutics (Xiamen) Co., Ltd. Gastric residence article for oral administration
WO2025195482A1 (zh) * 2024-03-22 2025-09-25 厦门君德医药科技有限公司 一种胃滞留装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
US9622966B2 (en) * 2007-07-06 2017-04-18 Basf Corporation Gastroretentive composition on the basis of a water-soluble reaction product from a vinyl group-containing precursor
WO2011124953A2 (en) * 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
AU2011285554C1 (en) * 2010-08-06 2016-05-12 Endoshape, Inc. Radiopaque shape memory polymers for medical devices
NZ727659A (en) * 2014-06-11 2021-12-24 Massachusetts Inst Technology Residence structures and related methods
US11576859B2 (en) * 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
WO2017100367A1 (en) * 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
CN109310639A (zh) * 2016-05-27 2019-02-05 林德拉有限公司 用于胃驻留系统的材料结构
JP2019532947A (ja) * 2016-09-30 2019-11-14 リンドラ,インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
CA3066658A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
US11793751B2 (en) * 2017-09-20 2023-10-24 Lyndra Therapeutics, Inc. Encapsulation of gastric residence systems
KR20220002905A (ko) * 2019-03-25 2022-01-07 더글라스 파머수티클스 리미티드 서방형 약학 제제

Also Published As

Publication number Publication date
AU2020378438A1 (en) 2022-06-02
WO2021092491A1 (en) 2021-05-14
US20220387311A1 (en) 2022-12-08
EP4054545A1 (en) 2022-09-14
IL292849A (en) 2022-07-01
CA3160665A1 (en) 2021-05-14
CN115003335A (zh) 2022-09-02
BR112022008908A2 (pt) 2022-10-11
EP4054545A4 (en) 2024-02-14
JP2022553862A (ja) 2022-12-26

Similar Documents

Publication Publication Date Title
MX2022005494A (es) Sistemas de residencia gastrica para la administracion de agentes activos.
WO2023141524A3 (en) Dosage forms for gastric retention
Butini et al. Polypharmacology of dopamine receptor ligands
EP4218735A3 (en) Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP4455766A3 (en) Head-mounted-display system including three-dimensional knitted layer
AU2020379040A8 (en) Gastric residence systems having a filament for improved gastric residence
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
IL272274B2 (en) Antibodies 4h-7b Methods of using them
EP4076593A4 (en) SPRING LOADED MEDICAL NEEDLELESS INJECTION SYSTEM
WO2015112776A3 (en) Devices configured to provide treatment at an abreu brain thermal tunnel
MX2018008359A (es) Sistemas y métodos para preparación de plaquetas.
WO2008152115A3 (en) Drug-releasing polyelectrolyte coating, method for forming a drug-releasing polyelectrolyte coating, and implantable device
MX2019012479A (es) Sistemas ortoticos de retorno de energia.
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
PH12018500432A1 (en) Heteroaryl compounds and their use as therapeutic drugs
EP4385529A3 (en) Devices for controlled delivery
MX2022007315A (es) Formulaciones de olanzapina de liberacion sostenida.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
ZA202101156B (en) New attenuated virus strain and use thereof as a vaccine
MY165964A (en) Preventive or therapeutic agent for fibrosis
MX359757B (es) Produccion de color caramelo bajo en 4-metilimidazol (4-mei) clase iv.
MX2020006905A (es) Composiciones farmaceuticas liquidas orales de aminosalicilatos.
Frey et al. Stress
WO2015142865A3 (en) Metakaryocidal treatments
MX2020000118A (es) Composiciones y metodos para mejorar la funcion cardiaca.